durvalumab (imfinzi) Report issue

Biologics mAb Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Durvalumab is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).   Wikipedia

More Chemistry

Drug Pricing (per unit)

United States

$5.4193 - $7.1763


$739.6362 - $3081.8175
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

duravalumab | durvalumab | imfinzi | iph5401 and durvalumab | medi4736 | medi-4736 | nacolomab tafenatox


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue